Simplicity Wealth LLC Takes Position in Boston Scientific Corporation $BSX

Simplicity Wealth LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 11,274 shares of the medical equipment provider’s stock, valued at approximately $481,000.

Other large investors have also recently bought and sold shares of the company. Norges Bank purchased a new position in Boston Scientific during the 4th quarter worth $2,199,395,000. Bank of New York Mellon Corp purchased a new stake in shares of Boston Scientific in the second quarter valued at about $339,031,000. Assenagon Asset Management S.A. boosted its stake in shares of Boston Scientific by 133.6% during the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after buying an additional 5,751,760 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after buying an additional 3,907,981 shares during the period. Finally, Maverick Capital Ltd. purchased a new position in shares of Boston Scientific during the fourth quarter worth about $280,735,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 202,122 shares of company stock worth $9,813,931 in the last ninety days. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $51.46 on Tuesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a 50 day simple moving average of $46.12 and a 200-day simple moving average of $58.81. The company has a market cap of $74.58 billion, a price-to-earnings ratio of 20.83, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on BSX shares. Mizuho dropped their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Citigroup lowered their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. TD Cowen dropped their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.